Application of carbon nitride quantum dots

By using sugar and amino acids as raw materials in alkaline aqueous solution, the problems of high preparation conditions for carbon nitride quantum dots and poor biocompatibility in the prior art are solved, and the carbon nitride quantum dots are realized Antiangiogenesis, antibacterial and biosafety have promoted its application in the field of biomedical science.

CN119033811AInactive Publication Date: 2024-11-29SICHUAN XUANDU EYE OPTOMETRY TECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411288401.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure CN119033811A_ABST
    Figure CN119033811A_ABST
Patent Text Reader

Abstract

The invention discloses application of carbon nitride quantum dots, and belongs to the technical field of biological medicine. The application disclosed by the invention is the application of the carbon nitride quantum dots in preparation of anti-angiogenesis drugs. The carbon nitride quantum dots have good biocompatibility and an anti-angiogenesis effect. Tests show that in human umbilical vein endothelial cells, carbon nitride quantum dots which are not pre-incubated have an obvious anti-angiogenesis effect when the concentration is 1mg / ml, and carbon nitride quantum dots which are pre-incubated have an obvious anti-angiogenesis effect when the concentration is 0.3 mg / ml.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to an application of carbon nitride quantum dots. Background Art

[0002] Carbon nitride (C 3 N 4 ) is composed of carbon and nitrogen. As an organic semiconductor, it has been widely used in the fields of photocatalytic degradation, imaging, etc. As an emerging nanomaterial, Carbon Nitride Quantum Dots (CNQDs) generally refer to zero-dimensional carbon-nitrogen nanomaterials with dimensions less than 10nm. Due to its bright fluorescence, excellent stability, good water solubility and biocompatibility, low cost and low cytotoxicity, carbon nitride quantum dots have become a new type of fluorescent probe for biology and detection in recent years.

[0003] In the prior art, the preparation methods of carbon nitride quantum dots are mainly divided into two types: "top-down method" and "bottom-up method". The "top-down method" is to first use nitrogen-rich materials as precursors and synthesize bulk graphite phase carbon nitride (gC 3 N 4 ), then decompose and fragment it by various methods, and finally remove large particles by centrifugation to obtain carbon nitride quantum dots. Since bulk carbon nitride has strong CN bonds, strong acids, strong bases or long-term ultrasound are often used in its stripping process, which has the disadvantages of many process steps, high cost, imperfect structure, use of strong acids, strong bases or oxidants, and low yield. The "bottom-up method" uses nitrogen-rich small molecules as raw materials, first self-assembles and polymerizes to form a macromolecular system, and then decomposes and carbonizes the macromolecules through solvent thermal, hydrothermal, microwave and other synthetic routes. Although this method is simple to operate and can directly prepare carbon nitride quantum dots, most of the existing technologies use industrial reagents such as carbon tetrachloride, urea, ethylenediamine, and melamine as synthetic raw materials, and the reaction conditions are relatively high, such as calcining urea and melamine at 500-600°C, using concentrated nitric acid or strong bases, etc., resulting in a large amount of solvent required for cleaning and purification after preparation.

[0004] Therefore, the existing preparation technology of carbon nitride quantum dots has high reaction conditions and is not environmentally friendly, which seriously restricts the actual production and application of carbon nitride quantum dots. In addition, the use of concentrated strong acid or concentrated strong base in the preparation of carbon nitride quantum dots makes the prepared carbon nitride quantum dots have extremely poor biocompatibility, which basically eliminates their application in the biomedical field.

[0005] Patent CN110157422A discloses a method for preparing and applying amino carbon quantum dots, using histidine as a carbon source and a nitrogen source to synthesize amino carbon quantum dots with high fluorescence quantum yield by a one-step hydrothermal method. However, the method produces carbon quantum dots (CQDs) carrying amino groups, rather than nitrided carbon quantum dots.

[0006] At present, the research on carbon quantum dots (CQDs) is mostly focused on biological imaging using their fluorescent properties; for carbon nitride quantum dots (CNQDs), the existing technology only reports that carbon nitride quantum dots have antibacterial effects and can also be used as nanocarriers to load drugs. The existing technology has little research on the biological activity of carbon nitride quantum dots. Therefore, in-depth research on the biological activity of carbon nitride quantum dots and exploring their more clinical application possibilities have become issues that need to be urgently solved by technicians in this field. Summary of the invention

[0007] The purpose of the present invention is to provide an application of carbon nitride quantum dots, which is the application of carbon nitride quantum dots as active ingredients in the preparation of anti-angiogenic drugs.

[0008] The technical solution adopted by the present invention is as follows: The invention discloses an application of carbon nitride quantum dots, which is the application of carbon nitride quantum dots in the preparation of anti-angiogenesis drugs.

[0009] In some embodiments of the present invention, the drug contains carbon nitride quantum dots as the only active ingredient.

[0010] In some embodiments of the present invention, the diameter of the carbon nitride quantum dots in the drug is 2 to 5 nm.

[0011] In some embodiments of the present invention, the medicament comprises eye drops.

[0012] The carbon nitride quantum dots are produced by using sugar as a carbon source and amino acids as a nitrogen source in an alkaline aqueous solution at 50°C to 200°C through a Maillard reaction; The carbon source is selected from at least one of fructose, glucose, galactose and ribose; The nitrogen source is selected from at least one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine and histidine; The molar ratio of the carbon source to the nitrogen source is 1:2-20; The alkaline aqueous solution is selected from NaHCO with a concentration of 0.1 mol / L to 2 mol / L 3At least one of aqueous solution, NaOH aqueous solution, and ammonia aqueous solution.

[0013] In some embodiments of the present invention, the reaction temperature is 70-170°C.

[0014] In some embodiments of the present invention, the reaction temperature is 80-150°C.

[0015] In some embodiments of the present invention, the reaction time is 2 h to 48 h.

[0016] In the present invention, the molar ratio of the carbon source to the nitrogen source is 1:2-20; such as 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20.

[0017] In some embodiments of the present invention, the carbon source is galactose, the nitrogen source is histidine and cysteine, and the molar ratio of galactose, histidine, and cysteine ​​is 1:5:10; In some embodiments of the present invention, the carbon source is glucose and the nitrogen source is glycine; the molar ratio of glucose to glycine is 1:20; In some embodiments of the present invention, the carbon source is fructose, and the nitrogen source is alanine; the molar ratio of fructose to alanine is 1:2; In some embodiments of the present invention, the carbon source is ribose, the nitrogen source is leucine, and the molar ratio of ribose to leucine is 1:10; In some embodiments of the present invention, the carbon source is galactose and fructose, and the nitrogen source is leucine; the molar ratio of galactose, fructose and leucine is 1:1:10.

[0018] In the present invention, the reaction temperature is 50°C to 200°C, such as 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C, 95°C, 100°C, 105°C, 110°C, 115°C, 120°C, 125°C, 130°C, 135°C, 140°C, 145°C, 150°C, 155°C, 160°C, 165°C, 170°C, 175°C, 180°C, 185°C, 190°C, 195°C, and 200°C.

[0019] The reaction temperature is preferably 70 to 180°C, and more preferably 80 to 150°C.

[0020] The reaction time in the present invention is 2h to 48h, such as 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, 16h, 17h, 18h, 19h, 20h, 21h, 22h, 23h, 24h.

[0021] The concentration of the alkaline aqueous solution in the present invention is 0.1mol / L~2mol / L, such as 0.1mol / L, 0.2mol / L, 0.3mol / L, 0.4mol / L, 0.5mol / L, 0.6mol / L, 0.7mol / L, 0.8mol / L, 0.9mol / L, 1.0mol / L, 1.1mol / L, 1.2mol / L, 1.3mol / L, 1.4mol / L, 1.5mol / L, 1.6mol / L, 1.7mol / L, 1.8mol / L, 1.9mol / L, 2.0mol / L.

[0022] In some embodiments of the present invention, a purification step is further included after the Maillard reaction is completed.

[0023] In some embodiments of the present invention, the purification step comprises: centrifuging the reaction system cooled to room temperature, dialyzing the supernatant, and drying the dialyzed solution to obtain carbon nitride quantum dots.

[0024] Preferably, the drying is freeze-drying.

[0025] In some embodiments of the present invention, the centrifugation condition is centrifugation at 100 rpm to 10,000 rpm for 5 min to 30 min; preferably, centrifugation at 1,000 rpm for 20 min.

[0026] In some embodiments of the present invention, dialysis is performed for 2 h to 48 h using a 1000 Da to 5000 Da dialysis bag.

[0027] The invention discloses an eye drop, the only active ingredient of which is the carbon nitride quantum dots, and the eye drop also comprises a pharmaceutically acceptable carrier.

[0028] The "pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or vehicle that is administered together with a therapeutic agent and is suitable for contact with the tissues of humans and / or other animals within the scope of reasonable medical judgment without excessive toxicity, irritation, allergic response or other problems or complications corresponding to a reasonable benefit / risk ratio.

[0029] Compared with the prior art, the present invention has the following beneficial effects: The present invention is the first to discover that carbon nitride quantum dots have anti-angiogenic effects. Experiments have shown that in human umbilical vein endothelial cells (HUVEC), carbon nitride quantum dots without pre-incubation showed obvious anti-angiogenic effects at a concentration of 1 mg / ml, while pre-incubated carbon nitride quantum dots showed obvious anti-angiogenic effects at a concentration of 0.3 mg / ml.

[0030] In addition, carbon nitride quantum dots have peroxidase activity, which can make H 2 O 2 Produce hydroxyl free radicals; at the same time, carbon nitride quantum dots also have antibacterial effects, and their antibacterial effect on Staphylococcus aureus increases in a dose-dependent manner within the range of 0.1mg / ml~10mg / ml.

[0031] Carbon nitride quantum dots have good anti-inflammatory activity and can reduce the mRNA transcription of cytokines IL-6 and IL-1β in the mouse mononuclear macrophages (RAW264.7) inflammation model.

[0032] Carbon nitride quantum dots have good biosafety and have no obvious toxicity to organisms at small doses. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is an appearance diagram of carbon nitride quantum dots prepared by the present invention uniformly dispersed in an aqueous solution; Figure 2 Transmission electron microscope image of carbon nitride quantum dots prepared by the present invention; Figure 3 X-ray photoelectron spectrum of carbon nitride quantum dots prepared by the present invention; Figure 4 This is a graph showing the effect of different concentrations of carbon nitride quantum dots on HUVEC cell activity in the present invention, wherein CON represents the control group; Figure 5 The figure is a result of investigating the effects of different concentrations of carbon nitride quantum dots on the activity of human microglia cells (Human Microglia Cell 3, HMC3) in the present invention, wherein CON represents the control group; Figure 6 This is a graph showing the effect of different concentrations of carbon nitride quantum dots on the activity of RAW264.7 cells in the present invention, wherein CON represents the control group; Figure 7 This is a graph showing the results of investigating the anti-angiogenesis effects of carbon nitride quantum dots at different concentrations according to the present invention; Figure 8 The carbon nitride quantum dot aqueous solution of different concentrations in the substrate H 2 O 2 UV-visible absorption spectrum of 3,3',5,5'-tetramethylbenzidine oxidized under low temperature; Fig. 9 This is a graph showing the results of investigating the effect of carbon nitride quantum dots on the mRNA transcription of cytokine IL-6, wherein CON represents the control group; Fig.10This is a graph showing the results of investigating the effect of carbon nitride quantum dots on the mRNA transcription of the cytokine IL-1β, wherein CON represents the control group; Fig.11 This is a graph showing the results of an in vitro antibacterial plate test of the eye drops of the present invention. DETAILED DESCRIPTION

[0034] The specific embodiments of the present invention are described in further detail below in conjunction with the examples. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. The present invention encompasses all possible alternatives, improvements and equivalents within the scope of the claims. The specific techniques or conditions not specified in the following examples are all conventional techniques or conditions, or are carried out according to the techniques or conditions described in the literature in the art, or are carried out according to the product instructions.

[0035] Example 1 This embodiment discloses a method for preparing carbon nitride quantum dots of the present invention, comprising the following steps: (1) Dissolve 0.002 mol galactose, 0.01 mol histidine, and 0.02 mol cysteine ​​in 200 ml of 0.1 mol / L NaHCO 3 (2) dissolving the raw material in NaHCO 3 The aqueous solution was stirred and refluxed at 80 °C for 24 h; (3) After stirring and refluxing, wait for it to cool to room temperature and centrifuge at 1000 rpm for 20 min; (4) The supernatant after centrifugation was taken and dialyzed using a 1000Da dialysis bag for 12 h. The dialyzed solution was then freeze-dried to obtain carbon nitride quantum dots.

[0036] The carbon nitride quantum dots are weighed and dispersed in deionized water to obtain a carbon nitride quantum dot aqueous solution. The carbon nitride quantum dots are evenly dispersed in water, and their appearance is as follows: Figure 1 shown.

[0037] The transmission electron microscope image of the carbon nitride quantum dots prepared in this embodiment is as follows: Figure 2 As shown. Figure 2 It can be seen that the carbon nitride quantum dots are evenly dispersed and have a diameter of 2~5nm.

[0038] The X-ray photoelectron spectrum of the carbon nitride quantum dots prepared in this embodiment is as follows: Figure 3 As shown. Figure 3 It can be seen that the elemental composition and atomic valence state of the carbon nitride quantum dots indicate that the carbon nitride quantum dots were successfully prepared in this embodiment.

[0039] The yield of carbon nitride quantum dots in this example is 37.5%.

[0040] Example 2 This embodiment discloses a method for preparing carbon nitride quantum dots of the present invention, comprising the following steps: (1) Dissolve 0.002 mol of glucose as carbon source and 0.04 mol of glycine as nitrogen source in 200 ml of 1.2 mol / L NaHCO 3 In aqueous solution; (2) Dissolve the raw material in NaHCO 3 The aqueous solution was stirred and refluxed at 50°C for 48h; (3) After stirring and refluxing, wait for it to cool to room temperature and centrifuge at 1000 rpm for 20 min; (4) The supernatant after centrifugation was taken and dialyzed for 2 h using a 5000Da dialysis bag. The dialyzed solution was then freeze-dried to obtain carbon nitride quantum dots.

[0041] Take carbon nitride quantum dots, weigh them, and disperse them in deionized water to obtain a carbon nitride quantum dot aqueous solution.

[0042] The carbon nitride quantum dots prepared in this embodiment are evenly dispersed and have a diameter of 2-5 nm.

[0043] Example 3 This embodiment discloses a method for preparing carbon nitride quantum dots of the present invention, comprising the following steps: (1) Dissolve 0.002 mol fructose (carbon source) and 0.004 mol alanine (nitrogen source) in 200 ml of 2.0 mol / L NaHCO 3 In aqueous solution; (2) Dissolve the raw material in NaHCO 3 The aqueous solution was stirred and refluxed at 200 °C for 2 h; (3) After stirring and refluxing, wait for it to cool to room temperature and centrifuge at 800 rpm for 30 min; (4) The supernatant after centrifugation was taken and dialyzed for 24 h using a 3000Da dialysis bag. The dialyzed solution was then freeze-dried to obtain carbon nitride quantum dots.

[0044] Take carbon nitride quantum dots, weigh them, and disperse them in deionized water to obtain a carbon nitride quantum dot aqueous solution.

[0045] The carbon nitride quantum dots prepared in this embodiment are evenly dispersed and have a diameter of 2-5 nm.

[0046] Example 4 This embodiment discloses a method for preparing carbon nitride quantum dots of the present invention, comprising the following steps: (1) Dissolve 0.002 mol ribose (carbon source) and 0.02 mol leucine (nitrogen source) in 200 ml of 1.0 mol / L NaOH aqueous solution; (2) Stirring and refluxing the NaOH aqueous solution containing the raw materials at 150°C for 12 hours; (3) After stirring and refluxing, wait for it to cool to room temperature and centrifuge at 2000 rpm for 10 min; (4) The supernatant after centrifugation was taken and dialyzed using a 1000Da dialysis bag for 48 hours, and then the dialyzed solution was freeze-dried to obtain carbon nitride quantum dots.

[0047] Take carbon nitride quantum dots, weigh them, and disperse them in deionized water to obtain a carbon nitride quantum dot aqueous solution.

[0048] The carbon nitride quantum dots prepared in this embodiment are evenly dispersed and have a diameter of 2-5 nm.

[0049] Example 5 This embodiment discloses a method for preparing carbon nitride quantum dots of the present invention, comprising the following steps: (1) Dissolve 0.001 mol galactose and 0.001 mol fructose as carbon sources and 0.01 mol leucine as nitrogen source in 200 ml of 1.0 mol / L ammonia solution; (2) Stirring and refluxing the aqueous ammonia solution containing the raw materials at 170°C for 12 hours; (3) After stirring and refluxing, wait for it to cool to room temperature and centrifuge at 2000 rpm for 10 min; (4) The supernatant after centrifugation was taken and dialyzed for 24 h using a 2000Da dialysis bag. The dialyzed solution was then freeze-dried to obtain carbon nitride quantum dots.

[0050] Take carbon nitride quantum dots, weigh them, and disperse them in deionized water to obtain a carbon nitride quantum dot aqueous solution.

[0051] The carbon nitride quantum dots prepared in this embodiment are evenly dispersed and have a diameter of 2-5 nm.

[0052] Example 6 This embodiment discloses an eye drop with carbon nitride quantum dots as an active ingredient, and the preparation method thereof is as follows: S1: First prepare auxiliary ingredients: weigh vitamin E, sodium hyaluronate, and carbomer powder in a mass ratio of 2:5:1, mix the three evenly, and then sterilize with ultraviolet light; S2: First, use 50% of the total mass of injection water to dissolve the prepared auxiliary ingredients, stir while adding, and continue stirring for 60 minutes, and then add carbon nitride quantum dots; wherein the mass percentages of vitamin E, sodium hyaluronate, carbomer powder, and carbon nitride quantum dots in the eye drops are 0.2%, 0.5%, 0.1%, and 0.5%, respectively; S3: Finally, add osmotic pressure regulating solution to adjust the osmotic pressure, measure the pH value, use pH regulator to adjust the pH value to 6-7.5, add the remaining 50% of the total mass of water for injection, and continue stirring for 12 hours, filter out insoluble impurities, package in 2 mL bottles, and seal to obtain the finished product.

[0053] The pH regulator used was NaHCO 3 At least one of an aqueous solution and a citric acid aqueous solution.

[0054] Test Example 1 This test example discloses the cytotoxicity test of carbon nitride quantum dots of the present invention, which is as follows: Human microglia HMC3, human umbilical vein endothelial cells HUVEC, and mouse mononuclear macrophage RAW264.7 cells were plated in 96-well plates, with approximately 8×10 3 Each cell type was divided into 5 groups, namely, blank group (containing only culture medium), control group, and quantum dot treatment group (carbon nitride quantum dot concentrations were 1 mg / ml, 3 mg / ml, 10 mg / ml, and 30 mg / ml), with 3 wells in each group. After the cells adhered to the wall, they were treated according to the groups. Each group in the quantum dot treatment group was added with 10 μL of carbon nitride quantum dot aqueous solution of different concentrations, so that the final concentration of carbon nitride quantum dots in each group was 1 mg / ml, 3 mg / ml, 10 mg / ml, and 30 mg / ml, respectively. The cells were incubated at 37°C and 5% CO 2 The cells were treated for 24 h under the same conditions. After 24 h, 10 μL of CCK8 reagent was added and the cells were incubated at 37°C and 5% CO 2 The cells were incubated for 1 h under the same conditions and the OD value at 450 nm was measured using an enzyme-labeled instrument.

[0055] The carbon nitride quantum dots used in this test example were prepared according to the method of Example 1, and then different amounts of water were added to prepare carbon nitride quantum dot aqueous solutions of different concentrations.

[0056] The cell viability was calculated according to the following formula:

[0057] The test results are as follows Figure 4~Figure 6 As shown. The results show that when the concentration of carbon nitride quantum dots is 1mg / ml, there is no obvious toxicity to HUVEC, HMC3, and RAW264.7 cells; when the concentration of carbon nitride quantum dots is 3mg / ml, there is a certain inhibitory effect on cell activity; when the concentration of carbon nitride quantum dots is 10mg / ml and 30mg / ml, there is a significant inhibitory effect on cell activity. It can be seen that when the dosage of carbon nitride quantum dots is not more than 1mg / ml, it can be used in biomedicine.

[0058] Test Example 2 This test example discloses an anti-angiogenic activity test of carbon nitride quantum dots of the present invention. The carbon nitride quantum dots of this test example are prepared according to the method of Example 1. The specific test is as follows: HUVEC cells were plated in 96-well plates, with approximately 8 × 10 3 cells. A total of 9 groups were set up, including the control group, quantum dot pre-incubation group (the concentrations of carbon nitride quantum dots were 0.3 mg / ml, 1 mg / ml, 3 mg / ml, and 10 mg / ml), and quantum dot non-pre-incubation group (the concentrations of carbon nitride quantum dots were 0.3 mg / ml, 1 mg / ml, 3 mg / ml, and 10 mg / ml), with 3 wells in each group. After the cells adhered to the wall, they were treated according to the grouping. 10 μL of carbon nitride quantum dot aqueous solution of different concentrations was added to each quantum dot pre-incubation group, so that the final concentrations of carbon nitride quantum dots in each group were 0.3 mg / ml, 1 mg / ml, 3 mg / ml, and 10 mg / ml, respectively, and then incubated at 37°C and 5% CO 2 The cells were treated under the same conditions for 12 h. Angiogenesis assay was performed 12 h later.

[0059] The night before, pre-cool the 96-well plate, experimental pipette tips, and Matrigel in a 4°C refrigerator; the next day, take out the pre-cooled 96-well plate, add 50 μL of liquid Matrigel to each well to cover the bottom, and then place it in a 37°C incubator for 30 minutes to allow Matrigel to completely solidify. Take out the HUVEC cells, count them after digestion, and resuspend them in ECM complete medium at 1×10 4 The cells were seeded on Matrigel in a 96-well plate at a density of 10 cells / 50 μL. The cells used in the quantum dot pre-incubation group were cells pre-treated with carbon nitride quantum dot aqueous solution for 12 hours; the cells used in the other groups were HUVEC cells that were not treated with carbon nitride quantum dot aqueous solution.

[0060] After inoculation of cells, the quantum dot pre-incubation group and the quantum dot non-pre-incubation group still need to add 10 μL of carbon nitride quantum dot aqueous solution of different concentrations to make the final concentration the concentration of the corresponding group, and the control group is added with an equal amount of deionized water; then, the cells are incubated at 37°C and 5% CO 2 The cells were cultured under the same conditions and photographed under a microscope after 4 and 8 hours, respectively.

[0061] The experimental results are as follows Figure 7 The results showed that in HUVEC cells, the carbon nitride quantum dots without pre-incubation showed a significant anti-angiogenic effect at a concentration of 1 mg / ml, while the carbon nitride quantum dots with pre-incubation showed a significant anti-angiogenic effect at a concentration of 0.3 mg / ml.

[0062] Test Example 3 This test example discloses a peroxidase activity test of carbon nitride quantum dots of the present invention. The carbon nitride quantum dots of this test example are prepared according to the method of Example 1. The specific test is as follows: With 50 μmol / L H 2 O 2 The solution was used as a substrate and mixed with 0.4 mmol / L 3,3',5,5'-tetramethylbenzidine (TMB) solution in a volume ratio of 1:1.

[0063] The mixed solution was divided into six groups, 500 μL in each group, and 500 μL of 0 μg / mL, 5 μg / mL, 10 μg / mL, 20 μg / mL, 50 μg / mL, and 100 μg / mL of carbon nitride quantum dot aqueous solutions were added respectively. No carbon nitride quantum dot aqueous solution was added to the blank control group.

[0064] If carbon nitride quantum dots can make H 2 O 2 The solution produces hydroxyl radicals, which then oxidize 3,3',5,5'-tetramethylbenzidine (TMB) to produce a soluble blue product (Ox-TMB) with strong ultraviolet absorption at 620-650nm.

[0065] Different concentrations of carbon nitride quantum dots aqueous solution in substrate H 2 O 2 The UV-Vis absorption spectrum of 3,3',5,5'-tetramethylbenzidine oxidized under Figure 8 The results show that the aqueous solution of carbon nitride quantum dots can exhibit peroxidase activity, making H 2 O 2 Hydroxyl free radicals are generated, and the higher the concentration of the carbon nitride quantum dot aqueous solution, the higher the peroxidase activity it exhibits.

[0066] During bacterial infection, the rapid reproduction of bacteria will form a special microenvironment, including a decrease in pH (4.5-6.5) caused by anaerobic glycolysis and a high level of hydrogen peroxide (H 2 O 2 ) content, etc. At this time, the nanoparticles with enzyme-like activity can convert H 2 O 2 Converted into active hydroxyl radicals (•OH), the free radicals can cause lipid peroxidation of bacterial cell membranes and damage internal proteins and genes, thereby causing broad-spectrum antibacterial and bactericidal effects. The carbon nitride quantum dots with peroxidase activity provided by the present invention can utilize the special microenvironment of bacteria to play an antibacterial role, with a broad spectrum and high efficiency, can effectively control the formation of drug-resistant bacteria, and have bacterial specificity and few adverse reactions.

[0067] Test Example 4 This test example discloses an antibacterial activity test of carbon nitride quantum dots of the present invention. The carbon nitride quantum dots of this test example are prepared according to the method of Example 1, and the positive drug cefuroxime sodium is produced by Hubei Weideli Chemical Technology Co., Ltd., with a specification of 10 g / bottle. The specific test is as follows: Step 1. Resuscitate Staphylococcus aureus the night before and culture in an incubator at 37°C, 225 rpm overnight (12-14 hours). Measure the OD value the next day, dilute the bacterial solution, and adjust the bacterial OD value to 0.08-0.12.

[0068] Step 2. Dilute the carbon nitride quantum dots and the positive drug cefuroxime sodium with LB culture medium to prepare carbon nitride quantum dot solutions with concentrations of 0.1, 0.3, 1, 3, and 10 mg / mL, respectively; and a cefuroxime sodium solution with a concentration of 0.1 mg / mL.

[0069] Step 3. Take a 96-well plate, add 100 μL of drug solution to each well, then add 10 μL of bacterial solution, 3 wells per group; put it in an incubator at 37℃ and culture for 18 hours. Set up another 3 wells, add only bacterial solution without adding drug solution, as a negative control group.

[0070] The minimum inhibitory concentration was observed by naked eye.

[0071] The OD value was tested by an enzyme-labeled instrument and the inhibition rate was calculated. A blank culture medium was taken as a blank control group and its absorption value was measured by an enzyme-labeled instrument.

[0072]

[0073] The results are shown in Table 1: Table 1 Test results of antibacterial activity of carbon nitride quantum dots

[0074] Note: + means the bacterial solution is visibly turbid, - means the bacterial solution is visibly clear The results showed that carbon nitride quantum dots have the effect of inhibiting Staphylococcus aureus, and the antibacterial activity increases in a dose-dependent manner within the range of 0.10-10 mg / ml.

[0075] Test Example 5 This test example discloses an anti-inflammatory activity investigation test of the carbon nitride quantum dots of the present invention. The carbon nitride quantum dots of this test example are prepared according to the method of Example 1; the RNA extraction kit RNA Purification Kit used in this test is manufactured by Thermo Fisher Scientific (China) Co., Ltd.

[0076] The specific tests are as follows: RAW264.7 cells were plated in 6-well plates, with approximately 2 × 10 cells per well.5 Each cell type was divided into four groups: control group (CON), quantum dot treatment group (M1), inflammation induction group (M1+1), and inflammation induction + quantum dot treatment group (1), with 3 wells in each group. After the cells adhered to the wall, they were treated according to the groups: 2 μL of carbon nitride quantum dot solution was added to each well of the carbon nitride quantum dot treatment group to a final concentration of 1 mg / ml, and the cells were incubated at 37°C and 5% CO 2 Cells were cultured for 12 h under the same conditions. In the inflammation induction group, 2.5 μL of IFN-γ solution and 2 μL of LPS solution were added to each well to make the final concentration of IFN-γ 2.5 ng / mL and the final concentration of LPS 200 ng / mL. The cells were incubated at 37°C and 5% CO 2 The cells were cultured under the same conditions for 12 h to induce cell differentiation into M1 type. In the inflammation induction + quantum dot treatment group, 2 μL of carbon nitride quantum dot solution, 2.5 μL of IFN-γ solution and 2 μL of LPS solution were added to each well at the same time, so that the final concentration of FN-γ was 2.5 ng / mL, the final concentration of LPS was 200 ng / mL, and the final concentration of carbon nitride quantum dots was 1 mg / ml. Then, the cells were incubated at 37°C and 5% CO. 2 The cells were cultured for 12 hours under the same conditions; the control group was treated with an equal amount of deionized water. After 12 hours, RNA from each group of cells was extracted using the Thermo Fisher RNA Purification Kit, and then qPCR was performed using the Thermo Fisher QuantStudio7Pro.

[0077] The results are as follows Fig. 9 and Fig.10 The results showed that in the RAW264.7 cell inflammation model, carbon nitride quantum dots at a concentration of 1 mg / ml could reduce the mRNA transcription of cytokines IL-6 and IL-1β, which showed that the prepared carbon nitride quantum dots had anti-inflammatory activity.

[0078] Test Example 6 This test example discloses an in vitro antibacterial plate test of the eye drops prepared in Example 5, as follows: Three groups of LB culture media were prepared, of which the first group was used as a blank control group, the second group was dripped with 1.0 ml of the auxiliary material solution, and the third group was dripped with 1.0 ml of the prepared eye drops, and the three groups of culture media were co-cultured with Staphylococcus aureus at 37° C. Two parallel tests were conducted to observe the reproduction of Staphylococcus aureus in the LB culture medium after 24 h and 48 h.

[0079] The auxiliary material solution of this test example was prepared according to the preparation method of the eye drops in Example 5 without adding carbon nitride quantum dots.

[0080] The experimental results are as follows Fig.11As shown, in the LB medium with the eye drops, Staphylococcus aureus was significantly inhibited, while in the blank control group and the LB medium with the auxiliary material solution, Staphylococcus aureus reproduced normally and was affected. The results show that the eye drops of the present invention have a significant antibacterial effect, and the main component of the eye drops that exerts the antibacterial effect is carbon nitride quantum dots.

[0081] Finally, it should be noted that the above embodiments are only preferred embodiments of the present invention, which are used to illustrate the technical solution of the present invention, but not to limit it, and certainly not to limit the patent scope of the present invention. Any changes or modifications that are made to the main design concept and spirit of the present invention without any substantial meaning, and the technical problems they solve are still consistent with the present invention, should be included in the protection scope of the present invention; in addition, the direct or indirect application of the technical solution of the present invention in other related technical fields is also included in the patent protection scope of the present invention.

Claims

1. An application of carbon nitride quantum dots, characterized in that: Application of carbon nitride quantum dots in the preparation of anti-angiogenic drugs.

2. The use according to claim 1, characterized in that: The drug contains carbon nitride quantum dots as the only active ingredient.

3. The use according to claim 1 or 2, characterized in that: The diameter of the carbon nitride quantum dots in the drug is 2-5 nm.

4. The use according to claim 1 or 2, characterized in that: The medicine includes eye drops.

Citation Information

Patent Citations

  • Method for rapidly displaying latent fingerprints on smooth object surface by using carbon nitride quantum dot

    CN107576640A